Ansbert Gadicke - Dec 31, 2021 Form 5 Insider Report for Cullinan Oncology, Inc. (CGEM)

Role
Former Director, 10%+ Owner
Signature
/s/ Ansbert Gadicke
Stock symbol
CGEM
Transactions as of
Dec 31, 2021
Transactions value $
$1,509,033
Form type
5
Date filed
2/10/2023, 03:26 PM
Previous filing
Dec 7, 2021
Next filing
Jan 6, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CGEM Common Stock Options Exercise $1.51M +351K +143.5% $4.30 595K Dec 21, 2021 Direct
holding CGEM Common Stock 7.65M Dec 31, 2021 See Footnote F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CGEM Stock Option (Right to Buy) Options Exercise $0 -262K -100% $0.00* 0 Dec 21, 2021 Common Stock 262K $4.30 Direct F3
transaction CGEM Stock Option (Right to Buy) Options Exercise $0 -88.8K -100% $0.00* 0 Dec 21, 2021 Common Stock 88.8K $4.30 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is BioImpact Capital LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing partner of BioImpact Capital LLC.
F2 The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
F3 These options are fully vested.